Novo Nordisk rebrands GLP-1 therapy Wegovy as weight-loss product, positioning it as lifestyle drug
GLP-1 drugs have transformed the lives of millions and were originally promoted as medicines for obesity, a medical condition.
Recent advertising campaigns are now presenting these drugs as general lifestyle solutions, using slogans such as “Live lighter” and “Summer Glow Up”.
Novo Nordisk, the market pioneer, has changed its product language, no longer describing Wegovy as a “weight management” or “anti-obesity” medicine but as a “weight loss” drug.
The shift signals a broader move toward treating weight‑related therapies as consumer products, which could influence prescribing habits and reimbursement models.
This writeup was produced by pharmadog from original reporting by STAT.
Original headline: “STAT+: Once described as obesity medicines for ‘patients,’ GLP-1s are increasingly lifestyle drugs for ‘customers’”
read at STAT ↗
comments(0)
5-min edit window · permanent after that